The association has been a reliable partner in EU-funded projects for many years. The following sections list information on the completed key projects of the past years as well as the ongoing projects of the association.

With the NANO2LIFE project, the association took off in the field of nano-bioanalytics in 2004 and, together with its partners, focused in the following years primarily on the establishment of a nanomedicine network in Europe and the development of measures to accelerate the translation of nanomedicine products from science to the market.

Here, the association had a decisive influence on the successful implementation of the projects through its strategic expertise and its connections in various communities, as well as by bringing the bioanalytical expertise of the companies and universities from the region into the European consortia. Topics such as standardisation, harmonisation and regulation of new materials such as nanomaterials are repeatedly the focus of the projects in which the association participates.
Since 2017, the association's focus has expanded to include technologies for life sciences and health in addition to bioanalytics. The expertise and connections that the association has gathered at European level are now being profitably brought into the region, for example in the Enabling Networks Münsterland project.

Ongoing Projects

MACRAME (2022 – 2025)

Advanced Characterisation Methodologies to assess and predict the Health and Environmental Risks of Advanced Materials. The MACRAMÉ project aims to widen the development of harmonised test guidelines and guidance documents (OECD) and standards (CEN, ISO) to market-relevant Advanced Materials in their complex product matrices.

Completed Projects

MDRSupport@NRW (2021-2022)

The aim of the MDR-Support@NRW measure was and is to provide application-oriented support to the participating economic actors in North Rhine-Westphalia, but in particular to medical technology manufacturers, in overcoming the challenges and implementing the EU MDR, 2017/745 and EU IVDR, 2017/746 regulations. 

Enabling Networks Münsterland (2019-2022)

In the joint project Enabling Networks Münsterland, the project team developed methods and tools to support regional companies in the development of innovations and in the search for suitable technologies. The project thus supported small and medium-sized enterprises in the region in particular, which often do not have the capacities for comprehensive innovation management.

REFINE (2017-2022)

REFINE built an ecosystem of a community of stakeholders in regulation, industry, science, technology development, and end-users to advance a Regulatory Science Framework in Biomaterials and Nanomedicine. It was meant to identify and tackle the current challenges and gaps on the existing development of nanomedicine products.

NOBEL (2017-2020)

Europe has to innovate and develop nanomedicines and medical technologies with high value and high technological content, well protected IP, and ensuring both a clinical need and commercial opportunities of all new innovations. This can only be achieved by combining Key Enabling Technologies (KETs), among others nanotechnologies, photonics, robotics, advanced materials, biotechnologies and information technologies to get smarter medical devices and smarter nanomedicines. However, the translation from the preclinical proof of concepts toward the market requires a more integrated and streamlined ecosystem with less barriers between stakeholders and steps of innovative product development. The NOBEL project developed approaches to tackle these challenges. 

EU-NCL (2015-2019)

EU-NCL mission was to provide a trans-disciplinary testing infrastructure covering a comprehensive set of preclinical characterisation assays (physical, chemical, in-vitro and in-vivo biological testing) allowing researchers to fully comprehend the bio distribution, metabolism, pharmacokinetics, safety profiles and immunological effects of their medical nanoparticles. The emphasis of the EUNCL is to serve as a nexus for trans-disciplinary research, development and clinical applications of nanotechnology and help developers to prepare for regulatory application.

ENATRANS (2015-2017)

ENATRANS was established to support the translation of innovative projects in nanomedicine across different development stages – from the idea to the patient – and to expand knowledge on nanomedicine. Its keystone is the Translation Advisory Board (TAB), a newly created instrument that allows ambitious European projects on nanomedicine to receive free advice and assistance by first-class, recognised experts from the industrial sector.

Nano2Life (2004 -2008)

NANO2LIFE was the first European Network of Excellence in nanobiotech supported by the Sixth Framework Programme of European Commission. Its aim was to merge existing European expertise in the field of nanobiotechnology. These endeavours were undertaken in order to keep Europe as a competitive partner to the United States and Asia. NANO2LIFE has consolidated the basis for Europe as a key player in the field of nanobiotechnology and was the start for a lively nanomedicine community in Europe by initiateing the ETPN (European Technology Platform for Nanomedicine) which is still successful in Europe. Our Association was one of the founding members of ETPN and is still involved as a board member.